Austin Myeloma Round Table

William Matsui, MD

William Matsui, MD, is Deputy Director of the LIVESTRONG Cancer Institutes, Professor in the Department Oncology and Director of Hematological Malignancies Program at the Dell Medical School at the University of Texas at Austin. He specializes in caring for patients with cancers that involve the blood and bone marrow as well as bone marrow transplantation. He came to Austin from the Johns Hopkins University School of Medicine, where he was a professor of oncology and served as the director of the Multiple Myeloma Program and the co-director of the Division of Hematologic Malignancies. Dr. Matsui has carried out laboratory-based translational research throughout his career and focused on studying cancer stem cells, tumor cells with enhanced growth potential and their role in clinical oncology. His laboratory first identified cancer stem cells in the plasma cell malignancy multiple myeloma in 2003 and subsequently in other cancers including lymphomas, leukemias and pancreas cancer. His laboratory has also demonstrated that several pathways regulating normal stem cells, including those involved in embryonic development, are abnormally activated in cancer stem cells. Dr. Matsui completed his residency training in internal medicine at the University of Washington in Seattle and his clinical training in medical oncology at Johns Hopkins. He earned his medical degree from the University of California at San Francisco.

Hans Lee, MD

Hans Lee, MD currently serves as the Director of Myeloma Research at Sarah Cannon Research Institute (SCRI). Prior to his move to SCRI, he was an Associate Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. He received his MD from Indiana University. Subsequently, he completed his internal medicine residency training at Washington University in St. Louis, followed by a hematology/oncology fellowship at MD Anderson Cancer Center. Dr. Lee's clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma and other plasma cell dyscrasias. In addition to his leadership role at SCRI, Dr. Lee serves as a medical oncologist at SCRI Oncology Partners in Nashville, Tennessee.

Syed Abbas Ali, MBBS

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health.

Matthew Butler

Dr. Matthew Butler is a faculty member of the division of hematology and oncology. Dr. Butler grew up in Nova Scotia, Canada, and worked in Toronto as a software developer before starting medical school. He completed his specialty training at UT Health San Antonio with a focus on blood cancers. His practice covers the full range of blood disorders, with a special interest in multiple myeloma. His clinical research focus is aimed at finding better treatments for malignant lymphomas